DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY

CSE: DTC          FSE: DTC          USOTC: DTCFF          PRESS RELEASE

DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY

Vancouver, BC, Canada, November 7^th, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, USOTC: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developing cutting-edge vaccines, therapeutics, and drug delivery technologies against cancer and other diseases, is pleased to announce that the Canadian Intellectual Property Office (CIPO) has issued a Notice of allowance for Defence’s Canadian patent application no. 3,201,103.

Canadian patent no. 3,201,103 (the ‘103 patent) broadly covers Defence’s key vaccine platform technologies that dramatically enhances the immunogenicity of protein subunit vaccines, improving their efficacy and potentially lowering antigen dose required to elicit a protective immune response. This Canadian patent includes important composition of matter claims that directly cover any protein subunit vaccine employing Defence’s technology, as well as claims covering their manufacture and use to fight cancer and infectious diseases. Defence’s counterpart US patent no. 11,291,717 was granted a few months ago.

“The fact that the CIPO decided to allow the ‘103 patent without issuing any examination report, and only one month after substantive examination started, is a strong testament to the innovative nature of Defence’s vaccine technology, as well as an acknowledgement by the Canadian government of the strength of Defence’s scientific data” says Mr. Sebastien Plouffe, the CEO of Defence Therapeutics.

Having already secured strong patent protection in two major vaccine markets – the Unites States and Canada – Defence intends to leverage the patents granted in these two jurisdictions to rapidly secure similar broad patent protection in other important markets, such as in Europe and Asia.

The issuance of the ‘103 patent bolsters Defence’s domestic patent portfolio and aligns with the Company’s objectives to advance their own novel clinical vaccine candidates. In addition, it creates new licensing and partnering opportunities, for example with manufacturers of approved protein subunit vaccines seeking to improve efficacy and prolong patent term of their products.

According to Precedence Research Predicts, the global oncology market size is expected to worth around US$ 536.01 billion by 2029 from valued at USD 286.04 billion in 2021 and growing at a CAGR of 8.2% from 2021 to 2030. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Rising concern about the cancer and patient is one of the major factors driving the market for the oncology market.

https://www.biospace.com/article/oncology-market-size-to-worth-around-us-536-01-bn-by-2029/

About Defence:

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM^TM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Splouffe@defencetherapeutics.com

www.defencetherapeutics.com

Cautionary Statement Regarding “Forward-Looking” Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.